Zevra Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Zevra Therapeutics, Inc. (ZVRA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $11.09 million as of 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2024-04-01
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $11.09M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $11.82M; Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed $11.82K.
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $254.21K.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $543.02K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2023-12-31 | $11.09M 10-K · filed 2024-04-01 | |
| 2022-12-31 | $11.82M 10-K · filed 2024-04-01 | $11.82K 10-K · filed 2023-03-07 |
| 2021-12-31 | $254.21K 10-K · filed 2023-03-07 | |
| 2020-12-31 | $543.02K 10-K · filed 2022-03-31 | |
| 2018-12-31 | $471.54K 10-K · filed 2019-03-01 | |
| 2017-12-31 | $471.54K 10-K · filed 2018-03-30 | |
| 2016-12-31 | $26.40K 10-K · filed 2018-03-30 | |
| 2015-12-31 | $9.20M 10-K · filed 2017-03-10 | |
| 2014-12-31 | $1.28M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |